Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5175263
Max Phase: Preclinical
Molecular Formula: C22H27F3N8O4S
Molecular Weight: 556.57
Associated Items:
ID: ALA5175263
Max Phase: Preclinical
Molecular Formula: C22H27F3N8O4S
Molecular Weight: 556.57
Associated Items:
Canonical SMILES: C[C@H]1OC(=O)N(c2nc(-c3cnc(N)nc3C(F)(F)F)cc(N3CCOCC3)n2)[C@H]1CN1CC[S+]([O-])CC1
Standard InChI: InChI=1S/C22H27F3N8O4S/c1-13-16(12-31-4-8-38(35)9-5-31)33(21(34)37-13)20-28-15(10-17(29-20)32-2-6-36-7-3-32)14-11-27-19(26)30-18(14)22(23,24)25/h10-11,13,16H,2-9,12H2,1H3,(H2,26,27,30)/t13-,16+/m1/s1
Standard InChI Key: GCSAIIBFWKMPEV-CJNGLKHVSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 556.57 | Molecular Weight (Monoisotopic): 556.1828 | AlogP: 1.15 | #Rotatable Bonds: 5 |
Polar Surface Area: 145.89 | Molecular Species: NEUTRAL | HBA: 11 | HBD: 1 |
#RO5 Violations: 2 | HBA (Lipinski): 12 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: | CX Basic pKa: 5.62 | CX LogP: 1.03 | CX LogD: 1.03 |
Aromatic Rings: 2 | Heavy Atoms: 38 | QED Weighted: 0.53 | Np Likeness Score: -1.02 |
1. Fairhurst RA, Furet P, Imbach-Weese P, Stauffer F, Rueeger H, McCarthy C, Ripoche S, Oswald S, Arnaud B, Jary A, Maira M, Schnell C, Guthy DA, Wartmann M, Kiffe M, Desrayaud S, Blasco F, Widmer T, Seiler F, Gutmann S, Knapp M, Caravatti G.. (2022) Identification of NVP-CLR457 as an Orally Bioavailable Non-CNS-Penetrant pan-Class IA Phosphoinositol-3-Kinase Inhibitor., 65 (12.0): [PMID:35500094] [10.1021/acs.jmedchem.2c00267] |
Source(1):